期刊文献+

罗丹明123经大鼠空肠黏膜的体外Ussing chamber渗透研究 被引量:4

Ussing chamber technique for in vitro study of permeability of rhodamine 123 through rat jejunum mucosa
下载PDF
导出
摘要 目的:检测并评价罗丹明123(R123)经空肠黏膜渗透的特点,分析此法的可行性。方法:配制R123溶液,采用体外Ussing chamber实验法,考察R123经时经大鼠空肠黏膜吸收方向和分泌方向的累计透过量,并计算各自渗透系数。结果:R123吸收和分泌方向的表观渗透系数Papp(×10-5,cm.s-1)分别为(1.9±1.3)和(7.4±5.2),差异具显著性。结论:R123作为P-糖蛋白的底物,其经肠黏膜渗透以分泌方向为主;Ussing chamber实验用于评价药物在肠道内转运具有易操作,简便等特点,值得推广使用。 OBJECTIVE To investigate the features of rhodamine 123 (R123) permeability through jejunum mucosa, and ana lyze feasibility of Ussing chamber in vitro. METHODS R123 solution was prepared. With in vitro Ussing chamber experiment , the accumulated amount of absorptive and secretory transport of R123 permeated through rat jejunum mucosa for was determined at different time points during the experiment, respectively. RESULTS The apparent permeability coefficient(Papp, × 10^-5 , cm·s^-1 ) of absorptive transport of rhodamine123 was (1.9 ± 1.3) significantly lower than that of secretory transport (7. 4 5.2). CONCLUSION As the substrat of P-glycoprotein(P-gp), the movement of R123 across the intestinal membranes was preferentially secretory direction; it is worth using Ussing chamber experiment because of the easy and feasible operation.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第17期1440-1442,共3页 Chinese Journal of Hospital Pharmacy
基金 2005年国家自然科学基金(编号:C03050205) 2005年广东省科技计划项目(编号:2005B30101007) 2006年笹川医学奖学金同学会科研启动基金(编号:101号)
关键词 罗丹明123 体外Ussing CHAMBER 回肠 表观渗透系数 rhodamine 123 in vitro Ussing chamber jejunum apparent permeability coefficient
  • 相关文献

参考文献12

  • 1Molden E. P-glycoprotein-a pump of significance for drug response[J].Tidsskr Nor Laegeforen, 2004, 124 (22) : 2921-2923.
  • 2Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy[J]. Curr Top Med Chem, 2004,4(13):1385-1398.
  • 3张伟霞,周宏灏.P-糖蛋白介导的药代动力学及其药物相互作用[J].中国临床药理学杂志,2004,20(2):139-143. 被引量:26
  • 4贺云霞,孙进,程刚.多药耐药性P-糖蛋白在药物肠道吸收中的作用[J].沈阳药科大学学报,2004,21(5):389-393. 被引量:23
  • 5Sachs-Barrable K, Thamboo A, Lee SD, et al. Lipid exeipients peceol and gelucire 44/14 decrease P glyeoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells[J]. J Pharm Pharmaceut Sci,2007,10(3) :319-331.
  • 6Aiko I, Mikio T, Yoko I,et al. Improvement of intestinal absorption of P-glycoprotein substrate by D-tartaric acid[J]. Drug Metab Pharmacokinet, 2006,21 (5) : 424-428.
  • 7杨振,秦环龙.Ussing chamber在肠道屏障功能研究中的进展[J].肠外与肠内营养,2006,13(4):233-236. 被引量:10
  • 8李国锋,陈建海,杨静,郭丹,任非,王春霞,侯连兵.地塞米松磷酸钠脂质体经兔结肠粘膜的体外Ussing chamber渗透研究[J].第一军医大学学报,2004,24(1):11-14. 被引量:9
  • 9Wallon C, Braaf Y, Wolving M, et al. Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular per meability in the human colon[J]. Scand J Gastroenterol,2005, 40(5):586-595.
  • 10Hua Yang, Robert Finaly, Daniel H. Alteration in epithelial permeability and ion transport in a mouse model of total parenteral nutrition[J].Crit Care Med, 2003,31 (4):1118-1125.

二级参考文献81

  • 1曾抗 李国锋 许重远 等.脂质体鬼臼毒素治疗尖锐湿疣的双盲随机对照试验[J].第一军医大学学报(J First Mil Med Univ/Di YiJun Yi Da Xue Xue Bao),1998,18(3):246-246.
  • 2[1]Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal Pglycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine[J]. Clin Pharmacol Ther, 1997;62:248-260.
  • 3[2]Maggio-Price L, Shows D, Waggie K, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdrla-/-)mice[J]. Am J Pathol, 2002; 160:739-751.
  • 4[3]Hunter J, Jepson MA, Tsuruo T, et al. Functional expression of Pglycoprotein in apical membranes of human intestinal Caco-2cells. Kinetics of vinblastine secretion and interaction with modulators[J]. J Biol Chem, 1993;268:14991-14997.
  • 5[4]Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol)caused by P-glycoprotein in the intestine[J]. Proc Natl Acad Sci USA, 1997;94:2031-2035.
  • 6[5]Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel[J]. J Clin Oncol, 2001;19:1160-1166.
  • 7[6]Masuda S, Uemoto S, Hashida T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient[J]. Clin Pharmacol Ther, 2000;68:98-103.
  • 8[7]Masuda S, Goto M, Kiuchi T, et al. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation[J]. Liver Transpl, 2003;9:1108-1113.
  • 9[8]Wetterich U, Spahn-Langguth H, Mutschler E, et al. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration-and dose-dependent absorption in vitro and in vivo[J]. Pharrn Res, 1996;13:514-522.
  • 10[9]Ueda CT, Lemaire M, Gsell G, et al. Apparent dose-dependent oral absorption ofcyciosporin A in rats[J]. Biopharmn Drug Dispos,1984;5:141-151.

共引文献57

同被引文献48

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部